Business Context and Reporting Period
Company: TriSalus Life Sciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 5, 2026
Reporting Period: Fourth quarter and full year ended December 31, 2025.
The filing serves as a notification that the Company issued a press release on March 5, 2026, announcing its financial results for the specified period. The press release is attached as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The provided Form 8-K text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the announcement of results for the fourth quarter and year ended December 31, 2025.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risks, contingencies, or unusual items. The document explicitly states that the information in the attached press release will not be deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 5, 2026) for actual financial figures, as they are not present in the 8-K body.
- Verify the Company's status as an emerging growth company (indicated as "o" in the filing, suggesting it is not currently checked or the status is not affirmed in this specific text block).
- Confirm the trading symbols: Common stock (TLSI) and Warrants (TLSIW) on the Nasdaq Global Market.
- Note that the press release content is not subject to Section 18 liabilities of the Exchange Act unless expressly referenced in other filings.